Investor Relations (IR) Questions: YM Biosciences YMI
Click here to return to the biotech IRQ Index
Answers received: September 2012
1) When is the last time YMI raised cash through an offering (diluted)?
YM raised $80.5 million in February 2012 at $2.00/share.
2) How much cash (not cash equivalents) does YMI have?
YM reported having ~$130 million in cash at June 30, 2012
3) What and approximately when is the next known catalyst?
YM anticipated reporting of Phase 2 results at ASH2012 conference in December 2012; Initiation of Phase 3 trials for CYT387; potential partnership to share in development of CYT387
4) What is YMI's quarterly cash burn?
We spent around $30 million over the last 12 months but that is expected to increase as Phase 3 trials ramp up.
5) Does YMI have an existing line of credit and if so how much can they draw against it?
No line of credit
1) When is the last time YMI raised cash through an offering (diluted)?
YM raised $80.5 million in February 2012 at $2.00/share.
2) How much cash (not cash equivalents) does YMI have?
YM reported having ~$130 million in cash at June 30, 2012
3) What and approximately when is the next known catalyst?
YM anticipated reporting of Phase 2 results at ASH2012 conference in December 2012; Initiation of Phase 3 trials for CYT387; potential partnership to share in development of CYT387
4) What is YMI's quarterly cash burn?
We spent around $30 million over the last 12 months but that is expected to increase as Phase 3 trials ramp up.
5) Does YMI have an existing line of credit and if so how much can they draw against it?
No line of credit